01 May 2026
01 May 2026
Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.
BMS is looking to Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy to drive growth into the 2030s.
The FDA’s decision is based on results from the Phase III ADVANCE-1 and ACCORD-2 studies.
The agreement is set to expand LEO Pharma’s pipeline in rare dermatology.
With $14.bn in projected revenue losses over six years, the Eliquis loss-of-exclusivity event is set to become one of the most consequential patent cliffs in pharmaceutical history — and a stark illustration of how quickly generic entry can dismantle even the industry's most entrenched brands.
Chiesi will assume ownership of Ekterly, an on-demand pill approved for hereditary angioedema.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
